Australia markets closed

Avalo Therapeutics, Inc. (AVTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
11.73-1.52 (-11.47%)
At close: 04:00PM EDT
12.03 +0.30 (+2.56%)
After hours: 07:19PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 12.13M
Enterprise value 5.25M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.69
Price/book (mrq)1.66
Enterprise value/revenue 2.73
Enterprise value/EBITDA -0.19

Trading information

Stock price history

Beta (5Y monthly) 1.22
52-week change 3-97.96%
S&P500 52-week change 325.59%
52-week high 31,130.40
52-week low 33.95
50-day moving average 310.74
200-day moving average 318.87

Share statistics

Avg vol (3-month) 3695.91k
Avg vol (10-day) 378.37k
Shares outstanding 51.03M
Implied shares outstanding 61.03M
Float 8860.98k
% held by insiders 15.74%
% held by institutions 16.28%
Shares short (15 Apr 2024) 4153.4k
Short ratio (15 Apr 2024) 40.08
Short % of float (15 Apr 2024) 414.83%
Short % of shares outstanding (15 Apr 2024) 414.83%
Shares short (prior month 15 Mar 2024) 467.18k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:240
Last split date 329 Dec 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-656.92%

Management effectiveness

Return on assets (ttm)-53.91%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)1.92M
Revenue per share (ttm)6.93
Quarterly revenue growth (yoy)-36.30%
Gross profit (ttm)N/A
EBITDA -23.29M
Net income avi to common (ttm)-31.54M
Diluted EPS (ttm)-114.00
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)7.42M
Total cash per share (mrq)7.17
Total debt (mrq)1.9M
Total debt/equity (mrq)26.05%
Current ratio (mrq)1.82
Book value per share (mrq)9.11

Cash flow statement

Operating cash flow (ttm)-30.68M
Levered free cash flow (ttm)-20.79M